Please, find the official information for patients, available in 7 different languages, under the following link: [here]
AG AG Pro Biosimilars published a film to biosimilars in oncology (in German)
To read the entire article (in German), visit: [link]
On 14th December 2017 our business partner Celltrion received the positive opinion for Herzuma® (trastuzumab biosimilar) from EMA´s CHMP for early breast cancer, metastatic breast cancer, and metastatic gastric cancer. More information can be found here.
In the recent “Innovation Report 2017” published by Prof. Dr. Gerd Glaeske, University of Bremen and Prof. Wolf-Dieter Ludwig, Chairman of the Drug Commission of the German Medical Profession, a special chapter focuses on the topic of “Biosimilars in oncology”. The authors emphasize the importance of biosimilars in patient care with modern, biological medicines. Consistent prescription of biosimilars by physicians, both for new prescriptions as well as when switching patients to a new medication, can result in cost savings.
In his foreword to the publication, Prof. Dr. Wolf-Dieter Ludwig discusses the fact that a large number of studies concerned with switching patients over to a biosimilar have shown that doing so has not resulted in disadvantages in terms of efficacy and side effects. In Europe, biosimilars are approved in accordance with a scientifically based and strictly controlled procedure to ensure that they are fully equivalent to the reference drugs and can also be used in the same manner.
According to Prof. Ludwig, “Biosimilars make an important contribution to providing patients with biological drugs that are already indispensable for the treatment of numerous illnesses.”
To read the entire article (in German), visit: [link]
Check out the new interview with Dr. Sabine Möritz-Kaisergruber and Mag. Helmut Kaisergruber at Pharmaboardroom.com. They are talking about Astro Pharma development, our vision and strategy:
In so called DANBIO registry study, the switch from Remicade to Remsima due to non-medical reasons was investigated in a total of 802 patients with rheumatoid arthritis, psoriasis arthritis and ankylosing spondylitis. The patients were treated with Infliximab for a median of already 6 years. The switch to Remsima does not have a negative effect on the disease activity. More information about the study is available in the corresponding concise report or in the summary in German language.
The results of the NorSwitch study (a switching study to the Infliximab biosimilar) confirm the safety for patients.
Find a press release and the related commentary as PDF documents to download below.
This information can also be downloaded here (published online from May 11, 2017).
The following link leads to the new information booklet on biosimilars, developed by EMA and European Commission:
On Thursday, 23.3.2017 Dr. Sabine Möritz-Kaisergruber, President of the Biosimilars Association, was invited to the 2-day IIR-conference, “Biosimilars – Acceptance in the Clinic / Reimbursement situation / Legal framework/ Pricing”. The title of her presentation was “Biosimilars – Hurdles and Ways to Success”.
This event was supported by top-class speakers, who among others included Prof. Josef Smolen, Rainer Schöfl, Michael Freissmuth. Topics like study design of biosimilars, approval of biosimilars in Europe, pricing and reimbursement situations and legal frameworks were discussed. There was also an outlook on current research conducted in the area of biosimilars. Among others, a presentation of Prof. Dr. Christian Huber should be noted; we gratefully share his interesting video on the Homepage of Biosimilars Association great video on the Homepage of Biosimilars Association(we would really recommend to watch it).
Prof. Tore Kvien (Norway) presented the Nor-Switch study in detail. In conclusion, Dr. Kaisergruber, with her presentation, refuted potential obstacles against the use of biosimilars. To support her point of view she cited current studies and relevant authorities.
Sabine Möritz-Kaisergruber, together with Mag. Martin Munte (President of Pharmig) and Dr. Ernst Agneter (pharmacologist and consultant), also joined a panel discussion on “Reimbursement and economic risks of biosimilars in Austria”. Dr. Clemens Auer (department leader in the Ministry of Health) unfortunately could not attend the event, so the discussion participants agreed quite quickly and mostly shared similar opinions.
In its latest position paper of January 2017, the European Society for Medical Oncology (ESMO) stresses the importance of biosimilars for the sustainable financing of cancer therapies (Tabernero et al., 2017). In a press release, ESMO President Professor Fortunato Ciardiello notes that.
There are currently no published data that do not support the use of biosimilars.
In their recently published paper, Ludwig and Dicheva (2016) emphasise the fact that, in addition to their savings potential in health systems (biosimilars as sustainable economic alternatives to biologics – often 20-30 percent less expensive than their reference product), biosimilars encourage competition in the pharmaceuticals market (Ludwig and Dicheva, 2016).
Current forecasts estimate a global market potential of 28 billion USD (approx. 25.9 billion Euros), with the prospect of a further increase to 35 billion USD (approx. 32.4 billion Euros) by 2020. In Europe, the potential savings are estimated at 20-40 percent, which could contribute to possible cost savings of 50-100 billion Euros by 2020 (Tabernero et al., 2017; Ludwig and Dicheva, 2016).
You can find out more about the Austrian Biosimilar Association (BiVÖ) in German here.
The official information for patients on biosimilars 2016 has been available since January 2017. This study on biosimilars by and for patients has been jointly supported by representatives of the European Medicines Agency (EMA), the European Commission and other interested parties [European Patient Forum (EPF), the European Crohns and Colitis Organisation (ECCO), Standing Committee of European Doctors (CPME), the European Federation of the Pharmaceutical Industries and Associations (EFPIA), the European Federation of the Bio-Industries (EuropaBio) and Medicines for Europe].
Please, find the official information for patients, available in 7 different languages, under the following link: Q&A on Biosimilar Medicines
Just like last year, Astro Pharma again supported the aid trips of Dr Euler-Rolle in 2016 with generous donations of drugs. Twice a year, Dr Euler-Rolle and his assistants bring aid shipments to families and hospitals in Romania and Moldova. We are committed to supporting this project whenever possible. You can read more under “Austria pro Moldavia”.